BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 17414630)

  • 1. Phase I/II study of irinotecan (CPT-11) and S-1 in the treatment of advanced gastric cancer.
    Katsube T; Ogawa K; Ichikawa W; Fujii M; Tokunaga A; Takagi Y; Kochi M; Hayashi K; Kubota T; Aiba K; Arai K; Terashima M; Kitajima M
    Anticancer Drugs; 2007 Jun; 18(5):605-10. PubMed ID: 17414630
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I/II trial of combination therapy with S-1 and weekly paclitaxel in patients with unresectable or recurrent gastric cancer.
    Inada S; Tomidokoro T; Fukunari H; Sato T; Hatano T; Nishimura A; Kawauchi Y; Nikkuni K; Shimizu T; Sato T; Yanagi M; Takahashi S; Yoshida H; Sugita M; Hayashi T
    Cancer Chemother Pharmacol; 2009 Jan; 63(2):267-73. PubMed ID: 18379784
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I/II study of CPT-11 plus UFT in patients with advanced/recurrent colorectal cancer: Osaka Gastrointestinal Cancer Chemotherapy Study Group (OGSG): Protocol 0102.
    Tomita N; Fukunaga M; Okamura S; Narahara H; Uedo N; Ishihara R; Ishida H; Furukawa H; Gotoh M; Takiuchi H
    Jpn J Clin Oncol; 2007 Jul; 37(7):521-7. PubMed ID: 17720738
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase 1/11 study of bi-weekly irinotecan plus cisplatin in the treatment of advanced gastric cancer.
    Koizumi W; Kurihara M; Satoh A; Takiuchi H; Tanabe S; Shimada K; Iwasaki R; Saigenji K
    Anticancer Res; 2005; 25(2B):1257-62. PubMed ID: 15865075
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase I trial of CPT-11 and S-1 combination chemotherapy in patients with metastatic colorectal cancer.
    Yamaguchi Y; Minami K; Kawabuchi Y; Ohshita A; Hironaka K
    Hepatogastroenterology; 2008; 55(82-83):407-11. PubMed ID: 18613376
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I study of a combination of s-1 and weekly paclitaxel in patients with advanced or recurrent gastric cancer.
    Ueda Y; Yamagishi H; Ichikawa D; Morii J; Koizumi K; Kakihara N; Shimotsuma M; Takenaka A; Yamashita T; Kurioka H; Nishiyama M; Morita S; Nakamura K; Sakamoto J
    Oncology; 2005; 69(3):261-8. PubMed ID: 16138002
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II study of a combination of irinotecan and S-1 in patients with advanced gastric cancer (OGSG0002).
    Uedo N; Narahara H; Ishihara R; Takiuchi H; Goto M; Fujitani K; Hirao M; Tsujinaka T; Imano M; Furukawa H; Tsukuma H; Taguchi T
    Oncology; 2007; 73(1-2):65-71. PubMed ID: 18334851
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I study of irinotecan and S-1 combination therapy in patients with metastatic gastric cancer.
    Yamada Y; Yasui H; Goto A; Arai T; Ura T; Hamaguchi T; Muro K; Shimada Y; Shirao K
    Int J Clin Oncol; 2003 Dec; 8(6):374-80. PubMed ID: 14663640
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I-II study of irinotecan hydrochloride combined with cisplatin in patients with advanced gastric cancer.
    Shirao K; Shimada Y; Kondo H; Saito D; Yamao T; Ono H; Yokoyama T; Fukuda H; Oka M; Watanabe Y; Ohtsu A; Boku N; Fujii T; Oda Y; Muro K; Yoshida S
    J Clin Oncol; 1997 Mar; 15(3):921-7. PubMed ID: 9060529
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase I study of bi-weekly combination therapy with S-1 and docetaxel for advanced or recurrent gastric cancer.
    Rino Y; Takanashi Y; Yukawa N; Saeki H; Wada H; Kanari M; Yamada R; Satoh T; Yamamoto N; Imada T
    Anticancer Res; 2006; 26(2B):1455-62. PubMed ID: 16619558
    [TBL] [Abstract][Full Text] [Related]  

  • 11. UFT/leucovorin plus irinotecan in advanced or metastatic colorectal cancer.
    Price T; Hill M
    Oncology (Williston Park); 2000 Oct; 14(10 Suppl 9):28-31. PubMed ID: 11098487
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Combination chemotherapy of S-1 and CPT-11 for advanced recurrent gastric cancer].
    Akasaka O; Iwase S; Miwa H; Ando T; Morita S; Koh R; Kasama M; Matsueda R; Anan H
    Gan To Kagaku Ryoho; 2009 Nov; 36(11):1833-7. PubMed ID: 19920384
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Irinotecan plus cisplatin therapy and S-1 plus cisplatin therapy for advanced or recurrent gastric cancer in a single institution.
    Nakashima K; Hironaka S; Boku N; Onozawa Y; Fukutomi A; Yamazaki K; Yasui H; Taku K; Kojima T; Machida N
    Jpn J Clin Oncol; 2008 Dec; 38(12):810-5. PubMed ID: 18988666
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I study of S-1 combined with irinotecan (CPT-11) in patients with advanced gastric cancer (OGSG 0002).
    Takiuchi H; Narahara H; Tsujinaka T; Gotoh M; Kawabe S; Katsu K; Iishi H; Tatsuta M; Fujitani K; Furukawa H; Taguchi T;
    Jpn J Clin Oncol; 2005 Sep; 35(9):520-5. PubMed ID: 16141295
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I/II study of irinotecan and UFT for advanced or metastatic colorectal cancer.
    Mibu R; Tanaka S; Futami K; Shimada K; Hotokezaka M; Nakahara S; Ichimiya H; Kido H; Hirano Y; Kashiwagi T; Eguchi T; Mitsuki K; Mizumoto K; Tanaka M
    Anticancer Res; 2007; 27(4C):2673-7. PubMed ID: 17695431
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I dose-finding and pharmacokinetic trial of irinotecan hydrochloride (CPT-11) using a once-every-three-week dosing schedule for patients with advanced solid tumor malignancy.
    Pitot HC; Goldberg RM; Reid JM; Sloan JA; Skaff PA; Erlichman C; Rubin J; Burch PA; Adjei AA; Alberts SA; Schaaf LJ; Elfring G; Miller LL
    Clin Cancer Res; 2000 Jun; 6(6):2236-44. PubMed ID: 10873073
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I study of combination therapy with S-1 and docetaxel (TXT) for advanced or recurrent gastric cancer.
    Yoshida K; Hirabayashi N; Takiyama W; Ninomiya M; Takakura N; Sakamoto J; Nishiyama M; Toge T
    Anticancer Res; 2004; 24(3b):1843-51. PubMed ID: 15274365
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized phase II trial of first-line treatment with tailored irinotecan and S-1 therapy versus S-1 monotherapy for advanced or recurrent gastric carcinoma (JFMC31-0301).
    Komatsu Y; Takahashi Y; Kimura Y; Oda H; Tajima Y; Tamura S; Sakurai J; Wakasugi T; Tatebe S; Takahashi M; Sakata Y; Kitajima M; Sakamoto J; Saji S
    Anticancer Drugs; 2011 Jul; 22(6):576-83. PubMed ID: 21512394
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activity and safety of a low dose, fractional administration of irinotecan hydrochloride (CPT-11) in combination with cisplatin for relapsed gastric cancer patients: a preliminary report.
    Shimoyama S; Aoki F; Shimizu N; Tatsutomi Y; Mafune K; Kaminishi M
    Int J Clin Oncol; 2003 Feb; 8(1):49-52. PubMed ID: 12601543
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase 1/2 clinical study of irinotecan and oral S-1 (IRIS) in patients with advanced gastric cancer.
    Komatsu Y; Yuki S; Fuse N; Kato T; Miyagishima T; Kudo M; Kunieda Y; Tateyama M; Wakahama O; Meguro T; Sakata Y; Asaka M
    Adv Ther; 2010 Jul; 27(7):483-92. PubMed ID: 20559897
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.